2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

dc.contributor.authorHerrstedt, J.
dc.contributor.authorClark-Snow, R.
dc.contributor.authorRuhlmann, C.H.
dc.contributor.authorMolassiotis, A.
dc.contributor.authorOlver, I.
dc.contributor.authorRapoport, Bernardo Leon
dc.contributor.authorAapro, M.
dc.contributor.authorDennis, K.
dc.contributor.authorHesketh, P.J.
dc.contributor.authorNavari, R.M.
dc.contributor.authorSchwartzberg, L.
dc.contributor.authorAffronti, M.L.
dc.contributor.authorGarcia-Del-Barrio, M.A.
dc.contributor.authorChan, A.
dc.contributor.authorCelio, L.
dc.contributor.authorChow, R.
dc.contributor.authorFleury, M.
dc.contributor.authorGralla, R.J.
dc.contributor.authorGiusti, R.
dc.contributor.authorJahn, F.
dc.contributor.authorIihara, H.
dc.contributor.authorMaranzano, E.
dc.contributor.authorRadhakrishnan, Venkatraman
dc.contributor.authorSaito, Mitsue
dc.contributor.authorSayegh, Paula
dc.contributor.authorBosnjak, S.
dc.contributor.authorZhang, L.
dc.contributor.authorLee, J.
dc.contributor.authorOstwal, V.
dc.contributor.authorSmit, T.
dc.contributor.authorZilic, A.
dc.contributor.authorJordan, Karin
dc.contributor.authorScotté, F.
dc.date.accessioned2024-03-12T07:59:20Z
dc.date.available2024-03-12T07:59:20Z
dc.date.issued2024-02
dc.description.abstractNausea and vomiting are still considered to be two of the most troublesome adverse events (AEs) for patients treated with antineoplastic therapy. To optimise the utility of available antiemetic prophylaxis, updated reviews of the relevant literature and evidence-based guideline recommendations are crucial. The European Society for Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC) completed the fourth Consensus Conference on Antiemetics for the prevention of nausea and vomiting in patients with cancer in Copenhagen in June 2015. This article is an update of the 2015 guidelines.en_US
dc.description.departmentImmunologyen_US
dc.description.librarianhj2024en_US
dc.description.sdgSDG-03:Good heatlh and well-beingen_US
dc.description.sponsorshipMeeting and production costs have been covered by MASCC and ESMO from central funds.en_US
dc.description.urihttps://www.esmoopen.comen_US
dc.identifier.citationHerrstedt, J., Clark-Snow, R., Ruhlmann, C.H. et al. 2024, '2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting', ESMO Open, vol. 9, no. 2, art. 102195, pp. 1-18, doi : 10.1016/j.esmoop.2023.102195.en_US
dc.identifier.issn059-7029 (online)
dc.identifier.other10.1016/j.esmoop.2023.102195
dc.identifier.urihttp://hdl.handle.net/2263/95143
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rights© 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license.en_US
dc.subjectPreventionen_US
dc.subjectNauseaen_US
dc.subjectVomitingen_US
dc.subjectMASCC–ESMO clinical practice guidelineen_US
dc.subjectRadiotherapyen_US
dc.subjectChemotherapyen_US
dc.subjectEuropean Society for Medical Oncology (ESMO)en_US
dc.subjectMultinational Association of Supportive Care in Cancer (MASCC)en_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.title2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomitingen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Herrstedt_MASCC_2024.pdf
Size:
542.68 KB
Format:
Adobe Portable Document Format
Description:
Article
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles (Immunology)
Research Articles (University of Pretoria)
Simple item page